marijuana stock news

Canna-Pet(TM) Launches Survey Investigating CBD Use in Animals

Company to Aid Scientific Inquiry With First Ever Public Survey of Its Kind

BOULDER, CO–(Marketwired – Feb 3, 2015) –Canna-Pet™ the leading American innovator of over-the-counter cannabinoid products for animals marketed by Peak Pharmaceuticals, Inc. (OTCQB: CTCO) is looking for volunteer participants to complete what may be the very first comprehensive nationwide survey investigating the use of CBD-based products for animals.

The survey can be found at https://canna-pet.com/hemp-products-for-pets-survey.

Company CEO Dr. Soren Mogelsvang states, “To the best of our knowledge, this survey represents the first research into product choice, frequency of use, target indications and outcomes for commercial hemp and cannabinoid based product use in animals.” He continues, “With research extremely limited for the past 75 years, due to its legal status, the safety and efficacy of cannabis-based products remain controversial, and it is critically important for us to build a scientific foundation to demonstrate safety and efficacy of cannabinoid products. The survey will contribute an important component of our ongoing efforts to elevate our understanding of cannabinoid use in animals and may support development of second generation products.”

Participants are advised the survey may take 5 to 10 minutes to complete and is completely anonymous. Because of the anonymity we can’t offer a thank you gift, other than the knowledge that your participation is greatly appreciated and we believe it will further the advancement of research into the amazing properties of hemp based cannabinoids including CBD. Please note that the survey ends February 28th.

About Canna-Pet™ Products for Pet Health
Canna-Pet™ is the culmination of years of research and development to provide the benefits of CBD and hemp without the “high” typically associated with THC. Today, Canna-Pet™ offers over-the-counter CBD products for cats, dogs and other domesticated animals. The company uses non-GMO hemp as starting material and all products are proudly made in the USA. In addition to CBD, Canna-Pet products contain proprietary ratios of other cannabinoids and terpenes. Canna-Pet™ is the leading producer of safe, hemp-based, cannabinoid (CBD) containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: CTCO). Order online at: www.canna-pet.com and join us on Facebook and Twitter.

For veterinary inquiries visit: www.canna-pet.com/contact/veterinary-inquiries.

FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.

Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company’s continuous public disclosure as a reporting issuer with the Securities and Exchange Commission (“SEC”) available at www.sec.gov. We seek Safe Harbor. For more information please visit www.peakpharma.com.

Contact:
For additional information, please contact:
Canna-Pet(TM) Support
support@canna-pet.com
www.canna-pet.com
www.peakpharma.com

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
1 comment
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Red White and Bloom Brands Inc. (RWBYF) Announces Upsized $25 Million Bought Deal Public Offering

Red White & Bloom Brands Inc. Announces Upsized $25 Million Bought Deal…

Canopy Growth Corporation (CGC) Announces Fall 2023 Investor Conference and Event Participation

Canopy Growth Announces Fall 2023 Investor Conference and Event Participation Canopy Growth…

GT Biopharma Inc. (GTBP) Announces Completion of First Four Patients in FDA Phase 2 Trial of Cancer Drug OXS-1550

GT Biopharma Announces Completion of First Four Patients in FDA Phase 2…

Canopy Growth Corporation (CGC) Reminds Shareholders to Cast Their Vote for Upcoming Annual General and Special Meeting

Canopy Growth Reminds Shareholders to Cast Their Vote for Upcoming Annual General…